Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites

Molecular Pharmacology

Volumn 74, Issue 4, 2008, Pages 1152-1162

  Uchaipichat, Verawan ^a   Galetin, Aleksandra ^b   Houston, J Brian ^b   Mackenzie, Peter I ^a   Williams, J Andrew ^c   Miners, John O ^a,d  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c PFIZER INC   (United States)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHOL; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE 2B7; HYMECROMONE; ZIDOVUDINE;

ARTICLE; AUTOREGULATION; BINDING AFFINITY; BINDING KINETICS; CATALYSIS; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; MICHAELIS MENTEN KINETICS; MOLECULAR MODEL; MULTIPLE EFFECTOR SITE; PRIORITY JOURNAL; SIGMOIDAL KINETICS;

ANTIMETABOLITES; BINDING SITES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYMECROMONE; INDICATORS AND REAGENTS; KIDNEY; KINETICS; NAPHTHOLS; SUBSTRATE SPECIFICITY; TRANSFECTION; ZIDOVUDINE;

EID: 52949103260     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.048645     Document Type: Article

References (40)

1. Boase S and Miners JO (2002) In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503.
2. Coffman BL, Kearney WR, Goldsmith S, Knosp BM, and Tephly TR (2003) Opioids bind to the amino acids 84 to 118 of UDP-glucuronosyltransferase UGT2B7. Mol Pharmacol 63:283-288.
3. Coffman BL, King CD, Rios GR, and Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73-77.
4. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133.
5. Davydov DR, Baas BJ, Sligar SG, and Halpert JR (2007) Allosteric mechanisms in cytochrome P450 3A4 studied by high pressue spectroscopy: Pivotal role of substrate-induced changes in the accessibility and degree of hydration of the heme pocket. Biochemistry 46:7852-7864.
6. Domanski TL, He YA, Khan KK, Roussel F, Wang Q, and Halpert JR (2001) Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 40:10150-10160.
7. Dubois SG, Beaulieu M, Lévesque E, Hum DW, and Bélanger A (1999) Alteration of human UDP-glucuronosyltransferase UGT2B17 regio-specificity by a single amino acid substitution. J Mol Biol 289:29-39.
8. Egnell AC, Houston B, and Boyer S (2003) In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 305:1251-1262.
9. Galetin A, Clarke SE, and Houston JB (2002) Quinidine and haloperidol as modifiers of CYP3A4 activity: Multisite kinetic model approach. Drug Metab Dispos 30: 1512-1522.
10. Galetin A, Clarke SE, and Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: Midazolam, testosterone, and nifedipine. Drug Metab Dispos 31:1108-1116.
11. He YA, Roussel F, and Halpert JR (2003) Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch Biochem Biophys 409:92-101.
12. Hosea NA, Miller GP, and Guengerich FP (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-5939.
13. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
14. Houston JB and Galetin A (2005) Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 233:351-360.
15. Jin C, Miners JO, Lillywhite KJ, and Mackenzie PI (1993) Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidatingcarboxylic acid-containing drugs. J Pharmacol Exp Ther 264:475-479.
16. Jin CJ, Mackenzie PI, and Miners JO (1997) The regio- and stereo- selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch Biochem Biophys 341:207-211.
17. Johnson EF and Stout CD (2005) Structural diversity of human xenobiotic metabolizing cytochrome P450 monooxygenases. Biochem Biophys Res Commun 338:331-336.
18. Kenworthy KE, Clarke SE, Andrews J, and Houston JB (2001) Multisite kinetic models for CYP3A4: Simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 29:1644-1651.
19. Kurkela M, García-Horsman JA, Luukkanen L, Mörsky S, Taskinen J, Baumann M, Kostiainen R, Hirvonen J, and Finel M (2003) Expression and characterization of recombinant UDP-glucuronosyltransfearses (UGTs). J Biol Chem 278:3536-3544.
20. Lewis BC, Mackenzie PI, Elliot DJ, Burchell B, Bhasker CR, and Miners JO (2007) Amino terminal domains of human UDP-glucuronosyltransferase (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochem Pharmacol 73:1463-1473.
21. Li Q, Lou X, Peyronneau MA, Straub PO, and Tukey RH (1997) Expression and functional domains of rabbit liver UDP-glucuronosyltransferase 2B16 and 2B13. J Biol Chem 272:3272-3279.
22. Mackenzie PI (1990) Expression of chimeric cDNAs in cell culture defines a region of UDP glucuronosyltransferase involved in substrate selection. J Biol Chem 265: 3432-3435.
23. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15: 677-685.
24. Meech R and Mackenzie PI (1997) UDP-Glucuronosyltransferases, the role of the amino terminus in dimerization. J Biol Chem 272:26913-26917.
25. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
26. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: Application of in vitro and in silico modelling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
27. Operaña TN and Tukey RH (2007) Oligomerization of the UDP-glucuronosyltransferase 1A proteins. J Biol Chem 282:4821- 4829.
28. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817-899.
29. Rios GR and Tephly TR (2002) Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1. Drug Metab Dispos 30:1364-1367.
30. Ritter JK, Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT, and Owens IS (1992) A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 267:3257-3261.
31. Shou M, Dai R, Cui D, Korzekwa KR, Baillie TA, and Rushmore TH (2001) A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem 276:2256-2262.
32. Stone AN, Mackenzie PI, Galetin A, Houston JB, and Miners JO (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: Evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086-1089.
33. Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, et al. (1999) Interaction of diclofenac and quinidine in monkeys: Stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291:1068-1074.
34. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
35. Turgeon D, Carrier JS, Lévesque E, Hum DW, and Bélanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787.
36. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
37. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: The effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
38. Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, and Miners JO (2007) Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics 17:1017-1029.
39. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, and Wrighton SA (2002) Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 30:1266-1273.
40. Wong H, Tong V, Riggs KW, Rurak DW, Abbott FS, and Kumar S (2007) Kinetics of valproic acid glucuronidation: Evidence for in vivo autoactivation. Drug Metab Dispos 35:1380-1386.